Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 7Thoracic 5CNS 3Plasma cell 2Other solid neoplasm 2Breast 2Other hematologic neoplasm 1Myeloid 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Melanoma 1Hereditary Sensory and Autonomic Neuropathies 1Dysplastic Nevus Syndrome 1

Interventions

pembrolizumab 161Nivolumab 133Ipilimumab 78Cyclophosphamide 47Specimen Handling 43Magnetic Resonance Spectroscopy 39cemiplimab 35Biopsy 31fludarabine 29trametinib 24relatlimab 24binimetinib 23Interleukin-2 22fludarabine phosphate 21dabrafenib 20atezolizumab 19Radiotherapy 19Opdualag 19aldesleukin 18Radiosurgery 18CTLA-4 Antigen 18encorafenib 17Blood Specimen Collection 17avelumab 14Immunoglobulin G 14Disulfides 13lifileucel 11lenvatinib 11Bevacizumab 11Paclitaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pharmaceutical Preparations × Dermatologic × 1 year × Clear all
NCT06599619 2026-01-26

Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi

University of Pittsburgh

Recruiting
30 enrolled
Dermatologic

Dysplastic Nevus Syndrome, Melanoma, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡